Background: Insomnia is common among people with mental health conditions and can exacerbate symptoms, impair functioning and negatively impact treatment outcomes. Community mental health services require practical data to quantify the burden of insomnia in routine care and to identify groups at a higher risk of experiencing clinically significant insomnia. Methods: We conducted a retrospective analysis of anonymized routinely collected clinical data from adult psychiatric outpatients attending the Community Mental Health Center in Bra (Department of Mental Health, Asl Cuneo 2, Italy). Consecutive patients were included over a three-month period (1 September to 30 November 2025). Insomnia severity was assessed using the Insomnia Severity Index (ISI). Diagnoses were established by psychiatrists using the Structured Clinical Interview for DSM-5 (SCID-5). Results: The sample included 506 patients (mean age: 45.1 ± 16.7 years; 265 women, 52.4%). The mean ISI total score was 12.18 ± 6.99. Clinically significant insomnia (ISI ≥ 15) was present in 205 out of 506 patients (40.5%), while severe insomnia (ISI ≥ 22) was present in 55 out of 506 patients (10.9%). The ISI score differed across diagnostic groups (ANOVA, F(8, 497) = 2.82, p = 0.0046, η2 = 0.043). Post hoc comparisons revealed higher ISI scores in patients with depressive disorders than in those with anxiety disorders (Tukey, p = 0.0056). In a multivariable logistic regression model (outcome: ISI score of at least 15), adjusted for age, sex, education and the complexity of concurrent psychotropic medication (number of medication classes), depressive disorders were associated with clinically significant insomnia (OR: 1.99; 95% CI: 1.07–3.73). Attention deficit hyperactivity disorder (ADHD) also showed higher odds (OR: 3.64; 95% CI: 1.26–10.55). Medication complexity was also associated with an ISI score of at least 15 (OR: 1.43 per additional class; 95% CI: 1.16–1.77). In a sensitivity model additionally adjusting for benzodiazepine prescription (yes/no), benzodiazepine prescription was associated with ISI ≥ 15 (OR 1.82; 95% CI 1.13–2.95), while the estimate for medication complexity was attenuated using this association (OR 1.17; 95% CI 0.90–1.53). The eating disorders group was excluded from multivariable models due to the very small sample size (n = 4). Conclusions: Clinically significant insomnia was prevalent among this sample of psychiatric outpatients, with modest differences in insomnia severity across diagnostic groups. Sensitivity analyses suggested that the signal of medication complexity may be partly accounted for by benzodiazepine prescribing, supporting the cautious interpretation of medication-related correlates in routine cross-sectional data. These findings support routine insomnia screening in psychiatric outpatient care, while prospective studies are needed to clarify directionality and clinical implications.
The diagnosis of early-onset bipolar disorder (EOBD) remains a major clinical challenge due to overlapping symptoms with other childhood psychiatric conditions and its divergence from adult presentations. There has been significant controversy over the phenomenology of EOBD due to the “Pediatric Bipolar Disorder” (PBD) proposed phenotypes, which, unlike adult mania, are often characterized by chronic irritability, affective instability, and mixed mood states rather than episodic euphoria. This case report presents B., a 12-year-old boy admitted for suicidal ideation and severe mood dysregulation. His history revealed early hyperactivity, oppositionality, progressive social withdrawal, somatic complaints, and persecutory ideation. Clinical assessment identified a major depressive episode with mixed features, supported by psychometric evidence of affective, anxiety, and somatic symptoms, as well as a cyclothymic–hypersensitive temperament. Treatment with lithium salts and aripiprazole led to significant clinical improvement, confirming the bipolar spectrum nature of his disorder. This case underscores the complexity of diagnosing “hidden bipolarity” in children, where irritability, anxiety, and subthreshold manic symptoms may obscure bipolar pathology. Although bipolar disorder was significantly overdiagnosed in prepubertal children in the past, B.'s case illustrates that rare peripubertal presentations can indeed manifest the phenomenological features described in the pediatric bipolar disorder literature.
Background: Insomnia is common and occurs across psychiatric diagnoses. A prior analysis of this outpatient cohort found that psychotropic medication complexity was associated with insomnia severity, but whether this association is stronger in particular diagnostic groups was not examined. We preregistered a moderation analysis to test whether mood disorder status modifies the association between medication complexity and insomnia, and additionally examined modification by sex and by insomnia domain. Methods: A secondary analysis was performed of cross-sectional, routinely collected data from 502 adult outpatients (from an initial cohort of 506) at an Italian community mental health centre. The primary model regressed the Insomnia Severity Index (ISI) total score on medication complexity × mood disorder status (depressive and bipolar vs. other psychiatric disorders), adjusting for age, sex and education; it was preregistered on the Open Science Framework before any interaction model was estimated. Results: Medication complexity was associated with the ISI total (b = 1.54 per class, 95% CI 0.92 to 2.16; attenuated but retained after benzodiazepine adjustment, b = 1.00, p = 0.009). The prespecified medication complexity × mood interaction was not statistically significant (b = −1.02, 95% CI −2.25 to 0.21, p = 0.103). The medication complexity × sex interaction was also non-significant (b = 0.28, p = 0.64), and the moderation did not differ between ISI domains (three-way interaction p = 0.67). Benzodiazepine prescription was independently associated with the ISI (b = 1.87, p = 0.011). Conclusions: The prespecified hypothesis of a stronger medication complexity–insomnia association in mood disorders was not supported. Because no equivalence margin was prespecified, the analysis cannot establish that the association is equivalent across groups; it indicates only that the hypothesised stronger association was not detected. Findings are exploratory with respect to mechanism and should be read in light of the cross-sectional design and probable confounding by indication.
Background: Insomnia is common and transdiagnostic in psychiatric care. A prior analysis of this community outpatient cohort found that psychotropic medication complexity was associated with insomnia severity, but whether this association is uniform across diagnoses was not examined. We preregistered a moderation analysis to test whether mood disorder status, or sex, modifies the association between medication complexity and insomnia. Methods: Secondary analysis of cross-sectional, routinely collected data from 506 adult outpatients (analytic N = 502) at an Italian community mental health centre. The primary model regressed the Insomnia Severity Index (ISI) total score on medication complexity × mood disorder status (depressive and bipolar vs. other), adjusting for age, sex and education; it was preregistered on the OSF before any interaction model was estimated. Results: Medication complexity was associated with ISI overall (b = 1.54 per class, 95% CI 0.92–2.16). The medication complexity × mood interaction was not significant (b = −1.02, 95% CI −2.25 to 0.21, p = 0.103; ΔR² = 0.005) and did not indicate a clinically meaningful stronger association in mood disorders. Slopes were positive in both groups (non-mood 2.03; mood 1.01 ISI points per class). There was no sex × mood moderation (p = 0.98), and benzodiazepine prescription was independently associated with ISI (b = 1.82, p = 0.013). Conclusions: In community psychiatric outpatients, medication complexity is a robust, transdiagnostic marker of insomnia severity that is not amplified in mood disorders or by sex. These preregistered findings support routine insomnia screening across the caseload, regardless of diagnosis, with prescribing intensity, benzodiazepines in particular, flagging patients who merit closer assessment focused on sleep.